tiprankstipranks
Urogen Pharma (URGN)
NASDAQ:URGN
US Market
URGN
Urogen Pharma
RESEARCH TOOLSreports

Urogen Pharma (URGN) Stock News & Sentiment

654 Followers
Building Momentum With Zusduri: Strong Early Commercial Traction, Expanding Physician Adoption, and Pipeline-Funded Upside Support a Buy Rating
Premium
Ratings
Building Momentum With Zusduri: Strong Early Commercial Traction, Expanding Physician Adoption, and Pipeline-Funded Upside Support a Buy Rating
1M ago
URGN
UroGen Pharma Earnings Call: Launch Momentum Meets Rising Costs
Premium
Company Announcements
UroGen Pharma Earnings Call: Launch Momentum Meets Rising Costs
1M ago
URGN
UroGen Pharma: ZUSDURI Launch Momentum, Strengthening Balance Sheet, and Path to Profitability Support Buy Rating
Premium
Ratings
UroGen Pharma: ZUSDURI Launch Momentum, Strengthening Balance Sheet, and Path to Profitability Support Buy Rating
1M ago
URGN
Trade Tensions Put UroGen Pharma’s Margins, Pipeline and Growth at Risk
Premium
Company Announcements
Trade Tensions Put UroGen Pharma’s Margins, Pipeline and Growth at Risk
1M ago
URGN
UroGen Pharma Secures New $250 Million Term Loan
Premium
Company Announcements
UroGen Pharma Secures New $250 Million Term Loan
1M ago
8K
URGN
URGN Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
URGN Upcoming Earnings Report: What to Expect?
1M ago
URGN
UroGen’s Phase 1 UGN-301 Bladder Cancer Trial Completion: What Investors Should Watch Next
Premium
Company Announcements
UroGen’s Phase 1 UGN-301 Bladder Cancer Trial Completion: What Investors Should Watch Next
3M ago
URGN
More URGN News >

URGN News on the Web

UroGen Pharma initiated with a Buy at Jefferies
TipRanks News
Bullish
UroGen Pharma publishes results from ENVISION trial of Zusduri
TipRanks News
Neutral
UroGen Pharma ‘commends’ BCAN release of Bladder Cancer Report
TipRanks News
Bullish
Building Momentum With Zusduri: Strong Early Commercial Traction, Expanding Physician Adoption, and Pipeline-Funded Upside Support a Buy Rating
TipRanks News
Neutral
UroGen Pharma Earnings Call: Launch Momentum Meets Rising Costs
TipRanks News
Bullish
Urogen Pharma Ltd at TD Cowen Healthcare Conference Transcript
GuruFocus News
Neutral
Guggenheim Sticks to Their Buy Rating for Urogen Pharma (URGN)
TipRanks News
Neutral
UroGen Pharma: ZUSDURI Launch Momentum, Strengthening Balance Sheet, and Path to Profitability Support Buy Rating
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
URGN
Sector Average
Media Buzz
This Week1 articles
Weekly Average1 articles
News Sentiment
This Week100%
Sector Average67%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is URGN’s Media Buzz Sentiment?
1 articles about URGN were published this week. In an average week, 1 articles are published.
    What is URGN’s weekly average amount of articles?
    In an average week, 1 articles about URGN are published.
      What is URGN’s News Sentiment?
      100% of articles about URGN were positive this week, compared to its sector average of 67%.
        Healthcare Stocks that are Trending in the News
        TXTMProText Mobility
        STAAStaar Surgical
        ALLOAllogene Therapeutics
        REPLReplimune Group
        IVVDInvivyd
        Showing the stocks with the most bullish news sentiment over the past week